<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1819">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137483</url>
  </required_header>
  <id_info>
    <org_study_id>IKC125</org_study_id>
    <nct_id>NCT05137483</nct_id>
  </id_info>
  <brief_title>Cognitive Impairment and Upper Extremity Performance in COPD</brief_title>
  <acronym>COPD</acronym>
  <official_title>Comparison of Upper Extremity Functional Capacity, Respiratory Functions, Fatigue and Quality of Life in Chronic Obstructive Pulmonary Patients With and Without Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Izmir Katip Celebi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Izmir Katip Celebi University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Within the scope of this study, COPD patients will be divided into two groups according to&#xD;
      cognitive dysfunction.&#xD;
&#xD;
      Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal&#xD;
      Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue&#xD;
      Impact Scale and St.George Respiratory Questionnaire will be applied to the groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the mechanism of cognitive dysfunction in COPD is not clear, the reasons focused on&#xD;
      are; decreased oxygen use, high carbon dioxide levels, increased inflammation and oxidative&#xD;
      stress, decreased physical activity, peripheral vascular diseases, atherosclerosis, high or&#xD;
      low blood pressure, cerebral vasoconstriction, increased intracranial pressure, accompanying&#xD;
      comorbidities, smoking and genetic predisposition, brain damage and exacerbations have been&#xD;
      reported. Few studies have shown that cognitive dysfunction is associated with functional&#xD;
      performance. There are no studies on the effect of cognitive function on upper extremity&#xD;
      performance and mechanisms of action in COPD patients.&#xD;
&#xD;
      The aim of this study is to compare upper extremity functional capacities, respiratory&#xD;
      functions, fatigue and quality of life in COPD patients with and without cognitive function&#xD;
      impairment.&#xD;
&#xD;
      Within the scope of this study, COPD patients will be divided into two groups according to&#xD;
      cognitive dysfunction.&#xD;
&#xD;
      Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal&#xD;
      Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue&#xD;
      Impact Scale and St.George Respiratory Questionnaire will be applied to the groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 19, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>6 min. pegboard ring test</measure>
    <time_frame>6 minutes</time_frame>
    <description>It is used to measure upper extremity functional capacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini Mental State Test</measure>
    <time_frame>15 minutes</time_frame>
    <description>It is used for measuring cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment Scale</measure>
    <time_frame>30 minutes</time_frame>
    <description>It is used for measuring cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Function Test</measure>
    <time_frame>20 minutes</time_frame>
    <description>It is used for measuring lung functions and respiratory muscle strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Impact Scale</measure>
    <time_frame>Time Frame: 20 minutes</time_frame>
    <description>It is used for measuring fatigue level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George Respiratory Questionnaire</measure>
    <time_frame>20 minutes</time_frame>
    <description>It is used for measuring desase-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Assessment Test</measure>
    <time_frame>10 minutes</time_frame>
    <description>It is used for measuring health status of COPD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mMRC Dyspnea Scale</measure>
    <time_frame>5 minutes</time_frame>
    <description>It is used for measuring dyspnea sensation in daily living activities</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COPD</condition>
  <condition>Upper Extremity</condition>
  <condition>Upper Limb Function</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>With cognitive impairment</arm_group_label>
    <description>Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without cognitive impairment</arm_group_label>
    <description>Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional tests</intervention_name>
    <description>We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.</description>
    <arm_group_label>With cognitive impairment</arm_group_label>
    <arm_group_label>without cognitive impairment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients above 45 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteering to participate in the study&#xD;
&#xD;
          -  Stage 2-3-4 according to the GOLD classification in the 40-65 age range&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exacerbation of respiratory symptoms in the past 4 weeks (change in breathlessness&#xD;
             and/or sputum volume/color, need for antibiotic treatment or need for hospitalization)&#xD;
&#xD;
          -  Presence of asthma, unstable coronary heart disease, uncontrolled diabetes,&#xD;
             hypertension, left-sided congestive heart failure, neoplasia, severe claudication,&#xD;
             encephalitis or epilepsy&#xD;
&#xD;
          -  Having a history of head trauma or brain tumor&#xD;
&#xD;
          -  Having a significant psychiatric condition or the presence of defined dementia,&#xD;
             according to the American Psychiatric Association&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Izmir Katip Celebi University</investigator_affiliation>
    <investigator_full_name>Ilknur Naz</investigator_full_name>
    <investigator_title>Assoc. Prof</investigator_title>
  </responsible_party>
  <keyword>copd</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>cognition</keyword>
  <keyword>upper extremity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

